

No.25-27

March 28, 2025  
Eisai Co., Ltd.

## **EISAI TO DIVEST RIGHTS FOR PARIET® IN CHINA TO PEAK PHARMA**

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that it has entered into an agreement to divest the rights for proton pump inhibitor Pariet® (generic name: rabeprazole sodium) in China to Beijing Peak Biology Pharmaceuticals Co., Ltd. (Headquarters: China, 北京顶峰生物医药有限公司 “Peak Pharma”), a CBC Group-controlled company. Peak Pharma has commenced marketing activities, while Eisai will manage the transfer of manufacturing and marketing authorizations during a transition period.

Under the terms of the agreement, Eisai will receive RMB725 million (approximately 15.7 billion JPY<sup>1</sup>) as contractual upfront payments, as well as the rights to receive a sales milestone payment. The upfront payments have already been recorded in the third quarter of Eisai’s fiscal year ending March 31, 2025. Eisai expects no changes to its consolidated financial forecast for the fiscal year ending March 31, 2025.

Pariet is a proton pump inhibitor (PPI) discovered and developed by Eisai, approved in more than 100 countries and regions worldwide. Pariet was approved in China in 2000 and is indicated for gastrointestinal disorders including gastric ulcer, duodenal ulcer, and reflux esophagitis. With the conclusion of this agreement, Eisai believes that CBC Group’s proven ‘investor-operator’ approach and commitment to delivering quality healthcare to a wide range of patients will maximize the value of Pariet in China.

The agreement will enable Eisai to strategically reallocate resources to other mid-to-long-term business growth areas so as to continue to make further contributions to address the diversified needs of, and increase the benefits provided to, patients and their families.

<sup>1</sup> Exchange rate: 1 RMB = 21.67 JPY (as of December 31, 2024)

Media Inquiries:  
Public Relations Department,  
Eisai Co., Ltd.  
+81-(0)3-3817-5120

**[Notes to editors]**

**1. About CBC Group**

Headquartered in Singapore, CBC Group is Asia's largest healthcare-dedicated asset management firm, with an AUM of US\$9 billion. With a diversified, multi-product strategy, CBC Group is focused on platform-building, buyout, private credit and royalties, and real estate, across the healthcare space, including pharmaceutical, biotech, medical technology, and healthcare services. We are committed to creating lasting value by integrating global innovations and talents. Partnering with the world's top entrepreneurs and scientists, our unique "investor-operator" approach has empowered leading healthcare companies to widen access to affordable medical care, catalyse innovations, and improve efficiencies in fulfilling unmet medical needs worldwide.

For more information on CBC Group, please visit [www.cbridgecap.com/](http://www.cbridgecap.com/). Connect with us on LinkedIn (CBC Group).